CMV-GFP AAV (Serotype MyoAAV4E)

CMV-GFP AAV (serotype MyoAAV4E) is an advanced viral vector with several significant advantages, particularly for gene delivery, especially to muscle cells. AAVs are highly attractive in the field of gene therapy because they can stably integrate into the host genome without causing significant damage to host cells, thus ensuring long-term transgene expression. The MyoAAV4E serotype specifically targets muscle tissue, improving transduction efficiency in skeletal muscle cells. This tissue specificity is primarily due to the unique capsid proteins of the MyoAAV4E serotype, which have been engineered to enhance binding affinity to muscle cell receptors, thereby facilitating more efficient gene delivery. Furthermore, this vector expresses a green fluorescent protein (GFP) reporter gene under the control of the cytomegalovirus (CMV) promoter. The CMV promoter is known for its strong and constitutive expression in a variety of tissues, thus enabling robust expression of the GFP marker, which can be easily monitored in transduced cells.

In the field of gene therapy, this viral vector holds promise for treating various muscle-related diseases, including muscular dystrophy and other myopathies. By specifically delivering therapeutic genes to muscle tissue, it can potentially correct the underlying genetic defects that cause these diseases. For example, researchers can utilize this vector to express genes that promote muscle repair or regeneration, providing a novel approach to mitigating muscle degeneration in affected patients. Additionally, its ability to express GFP allows researchers to visualize and track the efficiency of gene delivery and expression in real-time. This is particularly useful in preclinical studies, as monitoring the effects of gene therapy interventions can inform the design of future therapies. Furthermore, CMV-GFP AAV (MyoAAV4E) can be used to study muscle biology, including gene function and regulation in skeletal muscle development and physiology.